PDCD1 and neoplasm: PB1‐p62 in combination with the PD‐1 monoclonal antibody significantly prolonged the survival time of tumor‐bearing mice, suppressed tumor proliferation, and reduced tumor burden when compared with PD‐1 monoclonal antibody alone, suggesting that PB1‐p62 can enhance the efficacy of the PD‐1 monoclonal antibody (Figure 5J–M; Figure S6F,G and Tables S6 and S7, Supporting Information).